Get full access to The Daily Beast for $1 Anne Wojcicki regained control of the company she bankrupted after a $305 million bid. Andrew Harnik/Getty Images Former 23andMe CEO Anne Wojcicki is set to ...

New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase the bankrupt genetic testing firm 23andMe in a $256 million deal that could include millions of Americans' ...

Add Yahoo as a preferred source to see more of our stories on Google. Regarding 23andMe's massive DNA database, Regeneron said it plans to process the data "in ...

Amazon Prime Day isn't over just yet: The online retail giant is still dishing out deals on thousands of its best-selling products. Just when you thought you were all shopped out, Amazon rolls out ...

Regeneron Pharmaceuticals said Monday it will acquire 23andMe’s DNA testing business and most of its assets out of bankruptcy and pledged to continue offering the popular consumer service and adopt ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s privacy ...

The top bidder in the DNA testing firm's bankruptcy auction, Regeneron vows to prioritize the privacy, security, and ethical use of customer data. Following a data breach and bankruptcy, genetic ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy auction.

New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. This year, skip the clutter and gift pure ...

Law360 (May 12, 2025, 5:30 PM EDT) -- 23andMe's high-stakes plan to sell customers' genetic data in bankruptcy is poised to test the limits of court-appointed consumer privacy advocates in Chapter 11 ...